 |
The hope for a new era in Parkinson's treatment:
|
The world of medicine may be on the brink of one revolutionary development in the fight against Parkinson's disease, thanks to the discovery and research surrounding a special protein known as Cerebral Dopamine Neurotrophic Factor (CDNF). This development could not only improve the living standards of millions of those affected, but also offer a new way to treat neurodegenerative diseases.
Parkinson's disease, which affects seven to ten million people worldwide, results in a range of serious symptoms caused by the lack of dopamine, an important Chemic messenger in the brain. Although current treatments aim to correct this deficiency and relieve symptoms, they have no effect on its progression of the disease itself.
This is where CDNF comes into play. Research has shown that this naturally occurring protein has the ability to not only relieve symptoms but also potentially halt the progression of Parkinson's disease. What makes CDNF so special is its ability to be neuroprotective by protecting nerve cells from various forms of cellular stress that can ultimately lead to cell death. By protecting and regenerating the dopamine-producing neurons, CDNF offers an unprecedented opportunity to combat the disease.
The Out
demand However, the key to using CDNF lies in its administration. Because it is a protein, it cannot simply be taken as a pill or injected without losing its effectiveness. Therefore, current studies are testing an innovative drug delivery system implanted directly into the brain to effectively deliver CDNF to affected areas.
In addition to ongoing clinical trials, a project partner, Herantis, is launching a noninvasive CDNF development program to expand the protein's application and simplify its administration. This could open the door to broader use of CDNF in the treatment of Parkinson's and other neurodegenerative diseases.
The promising results and innovative approach of CDNF research mark a potential turning point in the treatment of Parkinson's disease. With every advance in this field, the hope for millions of sufferers worldwide of a life without the restrictions of this disease increases.
Summary:
| Key aspect | Declaration |
| Scope of disease | Parkinson's affects 7-10 million people worldwide; characterized by symptoms such as loss of motor control and cognitive impairment. |
| Current treatments | Focus on increasing dopamine levels and symptom relief; no influence on disease progression. |
| CDNF protein | May potentially relieve Parkinson's symptoms and stop disease progression. |
| administration the Herausforderung |
Direct administration into the brain required as oral intake/injection is ineffective. |
| Noninvasive development programs | Expanding the application and simplifying the administration of CDNF through noninvasive methods. |
| Potential influence | Could make a significant difference in the treatment of Parkinson's and other neurodegenerative diseases. |
Follow a manually added link
More articles on the topic “ to know better"
Can prasinezumab slow the progression of motor symptoms?
An article originally published in the Ärzteblatt is about the effect of the drug prasinezumab on motor symptoms. In a clinical trial, it was observed that the placebo group experienced a major worsening of their symptoms by 12,29 points. In the group treated with prasinezumab, this deterioration was significantly reduced - to just 4,39 points...
Diagnosis of Parkinson's and the correct initial therapy
Parkinson's is a neurological disease that affects the lives of millions of people worldwide, whether directly as sufferers or indirectly as relatives, carers or medical professionals. In this talk, we will strive to provide a comprehensive picture of Parkinson's, from the basics of the disease to current research and proven treatments. No matter whether you are already with...
Introduction to the world of Parkinson's - a lecture by Prof. Dr. Ceballos Baumann
Parkinson's is a neurological disease that affects the lives of millions of people worldwide, whether directly as sufferers or indirectly as relatives, carers or medical professionals. In this talk, we will strive to provide a comprehensive picture of Parkinson's, from the basics of the disease to current research and proven treatments. No matter whether you are already with...
The hope for a new era in Parkinson's treatment: CDNF in focus
The world of medicine may be on the verge of a revolutionary development in the fight against Parkinson's disease, thanks to the discovery and research surrounding a special protein known as Cerebral Dopamine Neurotrophic Factor (CDNF). This development could not only improve the living standards of millions of sufferers, but also offer a new way to treat neurodegenerative diseases...
The skin as a mirror of the brain
We all know the skin as the largest organ in our body - it protects us, regulates temperature and enables touch. But did you know that the skin can now also provide insights into the interior of our nervous system? Boston researchers have found that a protein called phosphorylated alpha-synuclein, which plays a key role in Parkinson's disease and other neurodegenerative diseases,...
Detect Parkinson's early, delay it, stop it or prevent it
In his lecture “Detecting Parkinson’s disease early, delay“, stop or prevent” Professor Oertel shares his extensive knowledge and many years of experience with us. Parkinson's disease, a progressive neurodegenerative disease, affects millions of people worldwide. Despite intensive research and development in treatment, it remains a major challenge for patients, families and healthcare professionals. Professor Oertel will guide us through the...
Stay tuned.
/
RSS Feed
Leave a comment
Participate in the discussion?Leave us your comment!